Page 188 - 2020_02-Haematologica-web

X. Poiré et al.
References
1. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor ver- sus no-donor analysis of myeloablative HLA-identical sibling stem cell transplanta- tion in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9): 3658-3666.
2. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta- analysis of prospective clinical trials. JAMA. 2009;301(22):2349-2361.
3. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommenda- tions from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
4. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136-1152.
5. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
6. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29-41.
7. Schoch C, Kern W, Kohlmann A, et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity char- acterized by genomic imbalances and a spe- cific gene expression profile. Genes Chromosomes Cancer. 2005;43(3):227-238.
8. Schlenk RF, Dohner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelat- ed donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28(30):4642-4648.
9. Stelljes M, Beelen DW, Braess J, et al. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica. 2011;96(7):972-979.
10. Versluis J, Hazenberg CL, Passweg JR, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):e427-e436.
11. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1997;90(8):2931-2938.
12. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
13. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute
myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
14. Haferlach C, Alpermann T, Schnittger S, et al. Prognostic value of monosomal kary- otype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood. 2012;119(9):2122-2125.
15. Jang JE, Min YH, Yoon J, et al. Single mono- somy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype. Blood Cancer J. 2015;5:e358.
16. Poire X, Labopin M, Maertens J, et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remis- sion: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol. 2017;10(1):20.
17. Castro PD, Liang JC, Nagarajan L. Deletions of chromosome 5q13.3 and 17p loci cooper- ate in myeloid neoplasms. Blood. 2000;95(6):2138-2143.
18. Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelodysplastic syn- drome are strongly correlated with aberra- tions of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013;160(5):660-672.
19. Stoddart A, Fernald AA, Wang J, et al. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood. 2014;123(7):1069-1078.
20. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
21. Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free sur- vival for registry-based studies: an ALWP- EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-611.
22. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
23. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96 (13):4075-4083.
24. Brands-Nijenhuis AV, Labopin M, Schouten HC, et al. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allo- geneic hematopoietic stem-cell transplanta- tion in first complete remission: a retrospec- tive survey on behalf of the ALWP of the EBMT. Haematologica. 2016;101(2):248-255.
25. Cornelissen JJ, Breems D, van Putten WL, et al. Comparative analysis of the value of allo- geneic hematopoietic stem-cell transplanta- tion in acute myeloid leukemia with mono- somal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012;30(17): 2140-2146.
26. Poire X, Labopin M, Cornelissen JJ, et al. Outcome of conditioning intensity in acute myeloid leukemia with monosomal kary-
otype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT). Am J Hematol. 2015;90(8):719-724.
27. Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comor- bidity index and Karnofsky performance status are independent predictors of morbid- ity and mortality after allogeneic nonmye- loablative hematopoietic cell transplanta- tion. Cancer. 2008;112(9):1992-2001.
28. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoi- etic cell transplantation. J Clin Oncol. 2014;32(29):3249-3256.
29. Lindsley RC, Saber W, Mar BG, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017;376(6):536-547.
30. Strickland SA, Sun Z, Ketterling RP, et al. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leuk Res. 2017;59:55-64.
31. Raza S, TaherNazerHussain F, Patnaik M, et al. Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopatho- logic correlates of sole abnormalities. Am J Hematol. 2011;86(4):353-356.
32. Middeke JM, Beelen D, Stadler M, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q. Blood. 2012;120(12): 2521-2528.
33. Breems DA, Van Putten WL, Lowenberg B. The impact of abn(17p) and monosomy - 5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. Blood. 2013;121(15):3056-3057.
34. Chilton L, Hills RK, Harrison CJ, et al. Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic sub- group of acute myeloid leukemia with dif- ferential outcome. Leukemia. 2014;28(2): 321-328.
35. Pusic I, Choi J, Fiala MA, et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2015;21(10):1761-1769.
36. Tsirigotis P, Byrne M, Schmid C, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016;51(11):1431-1438.
37. Yafour N, Beckerich F, Bulabois CE, et al. How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodys- plastic syndrome. Curr Res Transl Med. 2017;65(2):65-69.
38. Ades L, Prebet T, Stamatoullas A, et al. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies. Haematologica. 2017; 102(4):728-735.
39. Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia
422
haematologica | 2020; 105(2)